Table 3

Analysis of treatment on SWOV according to baseline CRP quartile†‡

QuartileCRP
(mg/L)
Kaplan-Meier estimate (n=450)HR
(95% CI)*
p value
LenzilumabPlacebo
1<41
(n=113)
54/56 (96)
(86 to 99)
47/57 (82)
(69 to 90)
8.20
(1.74 to 38.69)
0.0079
241<79
(n=112)
50/56 (89)
(77 to 95)
46/56 (82)
(69 to 90)
1.55
(0.58 to 4.15)
0.3860
379<137
(n=112)
40/47 (85)
(71 to 92)
48/65 (73)
(60 to 82)
2.25
(1.04 to 4.88)
0.0407
4≥137
(n=113)
45/62 (72)
(59 to 82)
37/51 (72)
(58 to 83)
1.17
(0.58 to 2.35)
0.6582
  • *Cox proportional hazard model for time to event with age (≤65,>65) and severity (severe, critical) strata as covariates.

  • †All data censored at 28 days following enrolment.

  • ‡mITT, modified intention to treat population; all participants with baseline CRP values collected.

  • CRP, C reactive protein; SWOV, survival without invasive mechanical ventilation.